Navigation Links
Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Date:10/3/2007

pment & Chief Medical Officer. "The 28-day endpoint will provide meaningful data on early viral kinetics and the proportion of patients who have undetectable HCV RNA by the end of this treatment period. We look forward to sharing the preliminary results of this combination study in the first quarter of 2008 and making plans for future studies of R7128."

About Pharmasset

Pharmasset is a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, an oral treatment for chronic HBV infection, is in Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a Phase 1 clinical trial through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

About R7128

R7128 is being developed for the treatment of chronic HCV infection. R7128 is a prodrug of PSI-6130, a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg.

R7128 Phase 1 Study Overview

The Phase 1 clinical trial is a multiple center, observer-blinded, randomized and placebo-controlled study to investigate the pharmacokinetics, pharmacodynamics, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chr
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 1, 2014   Intarcia Therapeutics, Inc. ... its four phase 3 clinical trials for ITCA 650 ... matchstick-sized, subcutaneous osmotic mini-pump). The first trial, FREEDOM-1, was ... the efficacy and safety of ITCA 650 in patients ... ITCA 650 to be significantly superior to placebo for ...
(Date:10/1/2014)... , Oct. 1, 2014 The ... available. Interested parties can learn about the ... Health is supporting the health care continuum ... . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... financials and the chief executive officer,s letter ...
(Date:10/1/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technology used to develop and produce enzymes and ... and industrial enzymes industries, today announced the receipt ... for commercial scale production of Abengoa,s proprietary cellulase ... under Abengoa,s license agreement with Dyadic. ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... Celldex also receives approval from Health Canada to ... collaboration with the National Cancer Institute, PHILLIPSBURG, ... the U.S. Food and Drug Administration (FDA) has,granted ... treatment of,EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is ...
... Jim Vandehei and John Harris ... The Politico, WASHINGTON, Dec. 6 , ... West Wing, 10:35 A.M. EST Q It,s an interesting time, ... on Capitol Hill right now.,But I,d love -- I mean, I,d love your overall assessment from -- ...
Cached Medicine Technology:Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 2Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 3Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 4Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme 5Interview of the Vice President 2Interview of the Vice President 3Interview of the Vice President 4Interview of the Vice President 5Interview of the Vice President 6Interview of the Vice President 7Interview of the Vice President 8Interview of the Vice President 9Interview of the Vice President 10Interview of the Vice President 11Interview of the Vice President 12Interview of the Vice President 13Interview of the Vice President 14Interview of the Vice President 15Interview of the Vice President 16
(Date:10/2/2014)... Dennis Thompson HealthDay ... Forty-two states and the District of Columbia now have a ... respiratory illness that has been infecting children since the ... with the virus have died in recent weeks, but it,s ... played in those deaths, officials said. Health officials are ...
(Date:10/1/2014)... today in the Journal of the American Medical ... years with moderate or severe chronic knee pain, acupuncture ... University of Melbourne randomly assigned 282 patients (50 years ... or sham or pretend laser treatment. , Treatments ... blinded to laser and sham (inactive) laser acupuncture. , ...
(Date:10/1/2014)... that encourages people to keep their "eyes on the ... exercise. When walking, staying focused on a specific target ... and help people walk there faster, psychology researchers have ... while looking around the environment naturally, offers a new ... are less interested in exercise if physical activity seems ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new ... insurance prices for smokers. , Smoking will always have ... quotes is the best method to find affordable coverage. ... who need coverage. , Whole life insurance premiums ... policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... October 01, 2014 Join the more than ... Disorder Treatment Center’s first ever charity golf tournament to benefit ... with eating disorders who cannot afford treatment. The tournament will ... in Eureka, Mo. , The day-long event starts with ... reception and award dinner will begin at 5 p.m. and ...
Breaking Medicine News(10 mins):Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... at PA Velodrome BREINIGSVILLE, Pa., April 26 In just ... Paradysz bested the 24-hour track record at the Valley ... a new record of 416.09 miles (669.63 kilometers) biked in ... was set in 1980. Paradysz undertook this daunting physical challenge ...
... A team of scientists at The Campbell Family ... Hospital and international collaborators have discovered how to trigger ... included in new clinical trials that use a patient,s ... online today in Nature Medicine (DOI: 10.1038/nm.1953), ...
... found they also reduced chances of erectile dysfunction , , ... statins help prevent prostate cancer and reduce the risk ... there seems to be mounting evidence that there may ... treatment or prostate cancer prevention," said Dr. Lionel L. ...
... Inc. and the California Family Health Council have released a statewide ... ... (PRWEB) April 26, 2009 -- ISIS, Inc., has partnered with the ... Health (CDPH), STD Control Branch, to launch a statewide text messaging ...
... statins may reduce inflammation in prostate tumors, possibly hindering ... in the Duke Prostate Center. , "Previous studies have ... lower incidence of advanced prostate cancer, but the mechanisms ... largely unknown," said Lionel Baez, M.D., a researcher in ...
... red under blue light allows physicians to more easily ... which these cancers come back, says a Mayo Clinic ... international clinical trial. , VIDEO ALERT: Additional audio and ... Lance Mynderse describing the research, are available on the ...
Cached Medicine News:Health News:Father Breaks Cycling Record To Honor Daughter's Fight Against Lupus 2Health News:Scientists discover how to improve immune response to cancer at Princess Margaret Hospital 2Health News:Statins Guard Against Prostate Cancer 2Health News:Statins Guard Against Prostate Cancer 3Health News:Statins Guard Against Prostate Cancer 4Health News:HookUp: Sexual Health Info Text Messaging Service for California Youth Launches 2Health News:Statins may exert influence on prostate cancer growth by reducing inflammation 2Health News:Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence 2Health News:Mayo Clinic researcher says improved detection of bladder tumors reduces cancer recurrence 3
5 mm tying platform. Round knurled handle with dull finish. Straight shafts. Overall length 3.9 inches....
Curved shafts with 12 mm tying platform. Serrated handle with polished finish. Overall length 4.3 inches....
Hartman Mosquito forceps, size 10 cm and made of Japanese S.S ....
Hartman Mosquito forceps, straight serrated jaws, ring handle, dull finish, overall length 75 mm....
Medicine Products: